Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Cydex Pharmaceuticals Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 1 distinct examiner and 1 distinct art unit, concentrating the entire pending portfolio under a specific point of review. This concentration suggests that the current legal strategy is focused on a technical advancement within the biotechnology sector.
The busiest examiner is ARNOLD, ERNST V, who is responsible for 2 busiest_examiner_pending. This examiner workload accounts for the entirety of the 2 pending office actions for the company, as there is only 1 distinct examiner involved in the current prosecution cycle. Such a structure means that the outcome of pending matters is currently tied to the decisions of ARNOLD, ERNST V.
Having 1 distinct art unit involved simplifies the administrative aspect of prosecution, as there are no competing procedural requirements from different units. The 2 pending office actions under the same examiner allow for a consistent dialogue during the application process. Practitioners can focus their efforts on the specific preferences and history of ARNOLD, ERNST V to manage the 2 busiest_examiner_pending effectively.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 2 | 48.2% | +12.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18244141 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | ARNOLD, ERNST V | 5d overdue |
| 18363940 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | ARNOLD, ERNST V | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18244141 | INJECTABLE MELPHALAN COMPOSITIONS COMPRISING A CYCLODEXTRIN DERIVATIVE AND METHODS OF MAKING AND USING THE SAME | ARNOLD, ERNST V | 1613 | §103 | Final Rejection | 5d overdue | Pending | Sep 08, 2023 |
| 18363940 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | 5d overdue | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial